Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study.
Digestive cryptosporidiosis (DC) can mimic GVHD after allogeneic haematopoietic stem cell transplantation (HSCT), thus requiring a reduction of immunosuppressive drugs and a specific therapy, whereas GVHD requires an intensification of immunosuppression. We systematically searched for cryptosporidiosis by light microscopy, immunochromatography and PCR in HSCT recipients who presented with at least one episode of diarrhoea. Of 115 consecutive patients allografted between July 2006 and November 2008, we analysed stools in 52 of 56 patients meeting these criteria. We identified Cryptosporidium parvum in 5 of the 52 patients (9.6%) at a median of 503 days (range 20-790) after HSCT. In those five patients, the median CD4+ cell and B lymphocyte counts were 60/mm3 (0-234) and 0/mm3 (0-96), respectively. Two patients died of invasive fungal infections. In the other three patients, diarrhoea disappeared after a median of 5 weeks following onset of bitherapy with azithromycine and nitazoxanide; they were still alive 433, 380 and 1179 days after the DC diagnosis. DC is probably under diagnosed after HSCT because it is difficult to detect during the asymptomatic phase. Early bitherapy and reduction of immunosuppression seem efficacious. In our series, DC has a seasonal pattern and is promoted by profound T lymphopenia.
Legrand
F
F
Service d'Hématologie Clinique, CHU Besançon, Hôpital Jean Minjoz, Besançon, France. flegrand@chu-besancon.fr
Grenouillet
F
F
Larosa
F
F
Dalle
F
F
Saas
P
P
Millon
L
L
Deconinck
E
E
Rohrlich
P S
PS
D000328:Adult; D000818:Animals; D017963:Azithromycin / Q000627:therapeutic use; D003457:Cryptosporidiosis / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D016785:Cryptosporidium parvum / Q000302:isolation & purification; D003937:Diagnosis, Differential; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008231:Lymphopenia; D008297:Male; D008875:Middle Aged; D009574:Nitro Compounds; D013844:Thiazoles / Q000627:therapeutic use; D014184:Transplantation, Homologous; D055815:Young Adult
D009574:Nitro Compounds; D013844:Thiazoles; D017963:Azithromycin; C041747:nitazoxanide